Reading Room Production — page 340

JJ contacted see she is a Lv of our I think she'll be most interested to sures Enterprise advanced with only n calling the cts are failing icacy. The C-private ollaboration. we are 'ive budgets but s where our t ight serve to rocess). he'll be > hadn't heard that you'd been selected for the position before JJ contacted me). > I'm actually in the late stages of negotiating a move to BARDA (the Biomedical > Advanced Research & Development Authority) as deputy director and I don't think JJ knew this when he spoke with you. It will be good to be coordinated > with you in that regard as well. > With respect to Heidi, she comes from the intelligence community so doesn't have a scientific or pharmaceutical background, but as you'll see she is a > very quick study. She oversaw White House coordination of the response to the pandemic and has been acutely sensitized to the deficiencies of our > countermeasures development efforts. I think she'll be most interested to hear about your and Dr. Collins's vision for CAN and how it will facilitate > translational efforts at NIH. > It's probably worth your reviewing the HHS Medical Countermeasures Enterprise Review document just to get your head in the game. For the better part of a > decade, our efforts on MCMs have focused on traditional government approaches to financing technology development (R&D funds for academia, advanced > development contracts for industry, and procurement contracts serving as the main "reward") with some twiddling of other pull incentives, with only > marginal success against threats we can define and not much progress in developing true rapid response capabilities. > The main conceptual novelty of MCMI is the focus on adjusting the cost side of > the equation by making strategic investments at what we've been calling the "chokepoints" of product development - the places where projects are failing > or dying on the vine for reasons other than lack of safety or efficacy. The overarching goal of MCMI is to change the nature of the public-private > partnership governing product development efforts in this area, changing the role of government from one of "funder" to active strategic collaboration. > This is where I think what we are doing will be of interest to you: we are using the national security imperative to maintain focus and drive budgets but > adopting an approach which ought to be fungible to other areas where our translational efforts are faltering. Heidi's goal won't be to co-opt CAN but > to think strategically with you about how what we are doing might serve to enhance our drug development efforts more broadly (and hopefully preserve the > competitiveness of the US biopharmaceutical industry in the process). > Happy to chat further but I think that's the kernel of what she'll be interested in discussing with you. > Do you have a brief bio you could send over by any chance? > Best regards, and I look forward to meeting you on Monday - > Richard > Best, Richard > > ----- Original Message ----- From: Ranganathan, Rajesh (NIH/OD) [C] @nih.gov > To: Hatchett, Richard J. Sent: Wed Nov 17 21:02:12 2010 > Subject: Re: Discussion about Cures Acceleration Network and the President's